Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15242977 | 0.97 | ADORA2A (0.39) | ADORA2AADORA3ADORA1 | |
| SCHEMBL20899905 | 0.87 | — | — | |
| SCHEMBL16856751 | 0.82 | ADORA2A (0.34) | ADORA2A | |
| SCHEMBL15242999 | 0.76 | CCNC (0.31) | — | |
| SCHEMBL17012839 | 0.76 | PSMB8 (0.37) | ADORA2AADORA3ADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15506668 | 0.73 | ADORA2A (0.37) | ADORA2ARAB9A | |
| SCHEMBL16856700 | 0.65 | CHRM5 (0.41) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20816387 | 0.64 | TSHR (0.33) | ADORA2AALDH1A1 | |
| SCHEMBL20816370 | 0.64 | TSHR (0.33) | ADORA2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15706621 | 0.64 | ALDH1A1 (0.36) | ADORA2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9388161-B2 | Tetrahydroquinoline compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256448-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ADORA2A 4120/4885ADORA3 2964/4885ADORA1 3026/4885 |
| US-20180215766-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ADORA2A 4120/4885ADORA3 2964/4885ADORA1 3026/4885 |
| US-20150232445-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ADORA2A 4120/4885ADORA3 2964/4885ADORA1 3026/4885 |
| US-20160257692-A1 | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ADORA2A 4120/4885ADORA3 2964/4885ADORA1 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.